Active — Not RecruitingNot Applicable

Targeting Oxidative Stress to Prevent Vascular and Skeletal Muscle Dysfunction During Disuse

United States82 participantsStarted 2019-09-01

Plain-language summary

Prolonged periods of reduced activity are associated with decreased vascular function and muscle atrophy. Physical inactivity due to acute hospitalization is also associated with impaired recovery, hospital readmission, and increased mortality. Older adults are a particularly vulnerable population as functional (vascular and skeletal muscle mitochondrial dysfunction) and structural deficits (loss in muscle mass leading to a reduction in strength) are a consequence of the aging process. The combination of inactivity and aging poses an added health threat to these individuals by accelerating the negative impact on vascular and skeletal muscle function and dysfunction. The underlying factors leading to vascular and skeletal muscle dysfunction are unknown, but have been linked to increases in oxidative stress. Additionally, there is a lack of understanding of how vascular function is impacted by inactivity in humans and how these changes are related to skeletal muscle function. It is our goal to investigate the mechanisms that contribute to disuse muscle atrophy and vascular dysfunction in order to diminish their negative impact, and preserve vascular and skeletal muscle function across all the lifespan.

Who can participate

Age range65 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age between 65-85 yrs * Ability to sign informed consent * Montreal cognitive assessment (MOCA) exam score greater-than or equal to 26 4. Free-living, prior to admission Exclusion Criteria: * Cardiac abnormalities considered exclusionary by the study physician (e.g., congestive heart failure (CHF), coronary artery disease (CAD), right-to-left shunt) * Uncontrolled endocrine or metabolic disease (e.g., hypo/hyperthyroidism, diabetes) * Glomerular filtration rate (GFR) less-than 30 mL/min/1.73m2 or evidence of kidney disease or failure * Vascular disease or risk factors of peripheral atherosclerosis. (e.g., uncontrolled hypertension, obesity, diabetes, hypercholesterolemia greater-than 250 mg/dl, claudication or evidence of venous or arterial insufficiency upon palpitation of femoral, popliteal and pedal arteries) * Risk of deep vein thrombosis (DVT) including family history of thrombophilia, DVT, pulmonary emboli, myeloproliferative diseases including polycythemia (Hb greater-than 18 g/dL) or thrombocytosis (platelets greater-than 400x103/mL), and connective tissue diseases (positive lupus anticoagulant), hyperhomocysteinemia, deficiencies of factor V Leiden, proteins S and C, and antithrombin III * Use of anticoagulant therapy (e.g., Coumadin, heparin) * Elevated systolic pressure greater-than 150 or a diastolic blood pressure greater-than 100 (treated or untreated) * Implanted electronic devices (e.g., pacemakers, electronic infusion pumps, stimulato…

What they're measuring

Change in blood vessel diameter after PLM

Timeframe: 10 days

Change in blood vessel flow rate after PLM

Timeframe: 10 days

Trial details

NCT IDNCT04351113

SponsorJoel Trinity

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-06-30